People

Search Language

中文(中国) / Simplified Chinese | Use language selector above (below, on mobile) to search additional languages
  • Selected filters
  • x(Technology Companies Group)

342 items matching filters

Practice:

  • Technology & Innovation Sector
  • Technology Companies Group
  • Fintech

Jamie Moore 合伙人

伦敦

Jamie acts for both early and late stage companies in intellectual property rich sectors and those who invest in them, including some of the most active venture capital funds, corporate or individual investors.

Jamie has a passion for disruptive technologies, innovation and entrepreneurial business. He has acted on countless transactions across a broad range of sectors both in the UK and internationally, but is most known for his experience in acting on investments into fintech and Artificial Intelligence companies.

Jamie has deep knowledge of the practice area in which he operates and market trends, which he leverages to provide clear and concise advice on a range of corporate issues taking high growth technology companies from start-up through to exit.

He presents on corporate law and venture capital to clients and at seminars in the City, including practitioners’ conferences on practical legal issues in venture capital transactions and SEIS/EIS investments.

An active participant in the venture capital community, Jamie Moore has contributed to industry standard form documentation, acted as a mentor for various Seedcamp portfolio companies and hosted office-hours for the Barclays' TechStars cohort.

740

Practice:

  • Finance Sector
  • 税务
  • 国际税务
  • Mergers & Acquisitions
  • Structured Finance
  • Energy & Infrastructure
  • Derivatives

John Narducci 合伙人

New York

John has extensive experience in stock and asset acquisitions, including tax-free reorganizations. He has represented purchasers, sellers and lenders in structuring acquisitions and negotiating the tax aspects of stock purchase and asset purchase agreements. Many of these acquisitions involved cross-border transactions.

Working with issuers, underwriters and investment funds, John has advised clients on numerous securities offerings, including securitization transactions, tender option bonds and high yield debt. Such offerings involved issuers in more than 40 countries.

John regularly works on the restructuring of transactions, including structured financings, project financings and energy and infrastructure projects. He advises on the tax planning aspects of such transactions.

Mr. Narducci has been involved in the development of tax-efficient financial structures, particularly in the cross-border context. For example, he has created tax-efficient structures for several investment funds. He also advises several financial institutions with respect to derivatives transactions, including the tax aspects of ISDA Master Agreements.

He also works with regulated and unregulated participants in the energy market on financings and a wide range of other transactions. Some of these transactions involve rural electric cooperatives.

John also advises on the tax aspects of pass-through entities, project financings and a broad range of other matters. He worked on the sovereign debt restructurings of Bulgaria, Costa Rica, Croatia, Nigeria, Poland and Vietnam.

449487

Practice:

  • 税务
  • Technology Companies Group
  • Banking & Finance

Nico Neukam 合伙人

杜塞尔多夫

His experience spans various industries, with a particular focus on advising companies in the growth and financial services sectors, often with an international scope.

Nico is listed by Legal 500 as a "Rising Star" and a "Recommended Lawyer" in tax law. His clients appreciate his forward-thinking solutions, which he develops proactively and in consensus with the tax authorities to ensure the best outcome for his clients.  

Nico Neukam joined Orrick in April 2024 after working for another international law firm for many years.

KT Nguyen 律师

西雅图

KT assists these companies with their legal needs as they expand, with a focus on corporate governance and venture financing. He also represents venture capital firms seeking to invest in these high growth companies.

KT graduated from the University of Washington School of Law, where he served as a Managing Editor of the Washington Law Review. He also was a member of the Entrepreneurial Law Clinic, where he advised entrepreneurs on early stage general corporate and intellectual property matters.

Prior to attending law school, KT was a graduate student researcher at the University of California, San Francisco. During grad school, he also worked in the technology transfer office where he helped to consult with inventors within the university to assess the patentability and commercialization prospects of their inventions.

456536

Practice:

  • Technology Companies Group

Lauren Nilles 律师

New York

Lauren also represents investors and venture capital firms in their investments in technology companies. 

Prior to joining Orrick, Lauren was an associate in the Corporate Group at Wilson Sonsini Goodrich & Rosati in New York. 

Practice:

  • Technology & Innovation Sector
  • Technology Companies Group
  • Mergers & Acquisitions
  • Life Sciences & HealthTech

Mike O'Donnell 合伙人

硅谷

Michael applies his broad experience in venture capital financings, public offerings, mergers and acquisitions, strategic alliances, technology licensing, and corporate spin-out transactions to each engagement. He has undertaken over 300 venture capital financings raising an estimated $7 billion for his clients, recently assisting Auris Health to raise over $650 million in financings before its sale to J&J for up to $5.75 billion.

He also brings extensive experience negotiating strategic alliances, representing clients in significant collaborations with GSK, Amgen, Schering-Plough, J&J, Daiichi, Astellas, King Pharmaceuticals, and most recently Pfizer, Merck, Baxter and Dainippon Sumitomo Pharma Co., Ltd.

Michael was the lead lawyer on the initial public offerings for Illumina, Neurocrine Biosciences, Cytokinetics, Pain Therapeutics, NeurogesX, Sequana Therapeutics, Ciphergen Biosystems, Argonaut Technologies, and Microcide Pharmaceuticals.

Michael was also the lead lawyer responsible for negotiating many notable biopharmaceutical spin-outs, including Onyx Pharmaceuticals (Chiron-Cetus), Tularik (Genentech), X-Ceptor (Ligand Pharmaceuticals), Metabasis (Gensia Sicor), and as well on the reverse merger of Transcept Pharmaceuticals with Novacea, creating a new publicly traded entity.